Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I trial for patients with intermediate or high risk myelodysplastic syndrome
(MDS).
The study agent, clofarabine, is produced by Genzyme Pharmaceuticals.